Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adalimumab in the treatment of immune-mediated diseases.
Lapadula G, Marchesoni A, Armuzzi A, Blandizzi C, Caporali R, Chimenti S, Cimaz R, Cimino L, Gionchetti P, Girolomoni G, Lionetti P, Marcellusi A, Mennini FS, Salvarani C. Lapadula G, et al. Among authors: blandizzi c. Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1 Suppl):33-48. doi: 10.1177/03946320140270S103. Int J Immunopathol Pharmacol. 2014. PMID: 24774505 Free article. Review.
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases.
Blandizzi C, Gionchetti P, Armuzzi A, Caporali R, Chimenti S, Cimaz R, Cimino L, Lapadula G, Lionetti P, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Girolomoni G. Blandizzi C, et al. Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1 Suppl):1-10. doi: 10.1177/03946320140270S101. Int J Immunopathol Pharmacol. 2014. PMID: 24774503 Free article. Review.
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.
Armuzzi A, Lionetti P, Blandizzi C, Caporali R, Chimenti S, Cimino L, Gionchetti P, Girolomoni G, Lapadula G, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Cimaz R. Armuzzi A, et al. Among authors: blandizzi c. Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1 Suppl):11-32. doi: 10.1177/03946320140270S102. Int J Immunopathol Pharmacol. 2014. PMID: 24774504 Free article. Review.
Risankizumab for the treatment of moderate to severe psoriasis.
Chiricozzi A, Antonioli L, Panduri S, Fornai M, Romanelli M, Blandizzi C. Chiricozzi A, et al. Among authors: blandizzi c. Expert Opin Biol Ther. 2019 Jan;19(1):1-8. doi: 10.1080/14712598.2019.1551354. Epub 2018 Nov 27. Expert Opin Biol Ther. 2019. PMID: 30462554 Review.
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients.
Bertani L, Tricò D, Pugliese D, Privitera G, Linsalata G, Zanzi F, Gloria Mumolo M, Barberio B, Monzani F, Marchi S, Guidi L, Blandizzi C, Armuzzi A, Costa F. Bertani L, et al. Among authors: blandizzi c. Aliment Pharmacol Ther. 2021 Jan;53(2):273-280. doi: 10.1111/apt.16167. Epub 2020 Nov 18. Aliment Pharmacol Ther. 2021. PMID: 33210332
290 results